In this free TechNote by SAMDI Tech, learn how the company’s radioactivity assays overcome key challenges in drug discovery by offering key solutions, including: Detecting low amounts of product with sensitive assays Generating data rapidly with high-throughput, 384-well capabilities Characterising potent inhibitors by benefiting from lower enzyme concentrations Learn… Read More
SAMDI Tech’s radioactivity assays overcome key challenges in drug discovery by offering key solutions, including: Detecting low amounts of product with sensitive assays Generating data rapidly with high-throughput, 384-well capabilities Characterising potent inhibitors by benefiting from lower enzyme concentrations In this free to download TechNote, learn how SAMDI Tech’s… Read More
Listen to this article on the DDW Podcast: Dr. Zack Gurard-Levin, Chief Scientific Officer, SAMDI Tech, breaks down three critical components to consider to ensure a successful affinity selection mass spectrometry (ASMS) drug discovery programme. The ability to rapidly identify small molecules that non-covalently bind to… Read More
In a clinical trial, Mount Sinai scientists gave immunotherapy to liver cancer patients before they received surgery and found that tumours died off significantly before surgery in a third of the patients, according to results reported in The Lancet Gastroenterology and Hepatology. The results The researchers… Read More
CliniSys has acquired Horizon Lab Systems and combined with Sunquest Information Systems, to create an organisation dedicated to diagnostic and laboratory informatics. Outlook CliniSys’ vision is to embrace a new wave of digital diagnostics and laboratories across the continuum of care and community to improve public health. Horizon… Read More
While the research, results and trials often take centre-stage when it comes to drug discovery and development reporting, DDW’s Megan Thomas spotlights the funding and investments which make this possible. 1. US researcher awarded $3.6 million to study antibiotic resistance Sanford Burnham Prebys professor Andrei Osterman, Ph.D., has… Read More
Listen to this article on the DDW Podcast: Lassi Paavolainen, Principal Investigator at the Institute for Molecular Medicine Finland (FIMM), Vilja Pietiäinen, Adjunct Professor in Cell and Molecular Biology, and Amanda Jones, Life Science Research Strategy Leader at PerkinElmer explain how functional precision medicine using ex vivo drug testing… Read More
Neurimmune has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical, which is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilising Neurimmune’s proprietary Reverse Translational Medicine (RTM) technology platform, an antibody drug creation approach. Background In November 2017, Ono and Neurimmune signed… Read More
Tokyo-based Takeda Pharmaceutical has optioned to acquire Adaptate Biotherapeutics, a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. The acquisition Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programmes. Adaptate’s γδ T cell engagers are… Read More
SLAS2022 in Boston is moving ahead as an in-person event with a hybrid component from February 5-9, 2022 at Boston Convention & Exhibition Center, which unsurprisingly has many from the drug discovery industry excited, including the DDW team, who will be stationed at Booth 1945. DDW has teamed up… Read More
PreOmics has raised €13.5 million in a Series B financing round provided by Bruker Corporation, which is expected to broaden the market opportunities for both PreOmics’ platform technologies and Bruker’s proteomics platform with more complete, automated workflow solutions for academic and clinical researchers, for biomarker discovery and diagnostics companies, as well as for… Read More
Listen to this article on the DDW Podcast: Last year a new translational research centre was established to bolster the University of Dundee’s drug discovery position. The Centre for Targeted Protein Degradation (CeTPD) would allow Professor Alessio Ciulli and colleagues to expand their pioneering work in an area that has… Read More
PhoreMost it has relocated its headquarters to Unity Campus, a high-specification technology and innovation park, designed to support PhoreMost’s phenotypic screening requirements and expertise. The new facility enables the company to add in-house flow cytometry and imaging capabilities. Dr Chris Torrance, CEO of PhoreMost, said: “Our move to Unity Campus follows… Read More
This is the latest episode of the free DDW podcast, “From here to there: What lies ahead for drug discovery”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW and read aloud by Megan Thomas. The articles are called “The complexity of disease… Read More
News round-up by DDW’s Megan Thomas for 17-21 January, 2022 When it comes to drug discovery and development, it’s all about the research, the breakthroughs and the next step. DDW’s Megan Thomas has rounded up five stories which highlight this theme of progress. 1. Read More
This is the latest episode of the free narrated DDW podcast, “From here to there: What lies ahead for drug discovery”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW and read aloud by Megan Thomas. The articles are called “… Read More
